康泰醫學(300869.SZ):相關產品通過美國FDA審核
格隆匯 5 月 9日丨康泰醫學(300869.SZ)公佈,近日,公司收到美國食品藥品監督管理局U.S. Food and Drug Administration (“FDA”)批准函,公司OTC類臂式電子血壓計CONTEC08A/CONTEC08C和動態血壓監護儀ABPM50通過美國FDA的510 (K)審核,獲准使用K號(K202757)。
OTC類臂式電子血壓計CONTEC08A/CONTEC08C和動態血壓監護儀ABPM50通過FDA審核後,此產品可以合法投放到美國市場。產品上市後實際銷售情況取決於未來市場的推廣效果,目前尚無法預測上述產品對公司未來營業收入的影響,敬請廣大投資者謹慎投資,注意防範投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.